Kelowna, BC – July 17, 2025 – TheNewswire – Doseology Sciences Inc. (CSE: MOOD | PINK: DOSEF | FSE: VU70) (“Doseology” or the “Company”), an innovator in precision-formulated oral stimulants, is pleased to announce the appointment of Patrick W. Sills as Strategic Go-to-Market Advisor.

Mr. Sills is an experienced commercial strategist with over 15 years of leadership in the nicotine and functional CPG sectors. His career includes senior roles with Philip Morris International and Fontem Ventures B.V., where he led initiatives in go-to-market strategy, product commercialization, and regulatory compliance within the nicotine pouch and reduced-risk product categories.

 

Mr. Sills has contributed to the success of several leading nicotine pouch brands and he notably led the management of the joint venture between Philip Morris International and Swedish Match. Through his firm, PWSILCORP, he has advised emerging brands on market entry, distribution strategy, and regulatory pathways across North America, Latin America, and Europe.

 

In his advisory role, Mr. Sills will support Doseology’s commercialization strategy, focusing on product positioning, distribution, regulatory considerations, and market expansion opportunities within the Company's oral stimulant portfolio.

 

Tim Corkum, President and COO of Doseology, stated, “Patrick’s industry expertise and proven track record in executing go-to-market strategies in highly regulated sectors will add significant value as we continue advancing Doseology’s position in the better-for-you nicotine and functional oral stimulant space. His advisory role aligns with our operational priorities as we focus on disciplined execution, accelerated market entry, and long-term growth.”

 

Recent market data highlights the growing potential of the oral nicotine pouch category. According to NielsenIQ data compiled by Goldman Sachs Global Investment Research (June 2025), the smokeless tobacco category—including oral nicotine pouches—grew by 13.4% year-over-year in the most recent two-week period, driven by both volume and pricing increases. Brands such as ZYN have gained notable market share, underscoring a continued shift toward alternatives in this product category. (The Company has not independently verified this third-party data and makes no representations as to its accuracy or completeness.)

     

Patrick W. Sills, Strategic Go-to-Market Advisor, added: “This market is at a pivotal moment. The growing demand for better-for-you alternatives presents a significant opportunity for companies that can move with speed, precision, and a strong product offering. Doseology is well-positioned to capitalize on this shift—not only through go-to-market execution, but also through disciplined M&A and roll-up strategies that expand its presence and operational scale. I look forward to supporting the Company’s next phase of growth.”

 

Chris Jackson, CEO of Doseology, added: “Our strategy is clear: to lead innovation in the oral stimulant category with a sharp focus on speed to market and operational excellence. Patrick’s experience with some of the most recognized pouch brands globally will be instrumental in helping us execute this vision and unlock long-term value for both consumers and shareholders.”

About Doseology Sciences Inc. (CSE: MOOD | PINK: DOSEF | FSE: VU70)

Doseology is a biotech innovation company, engineering precision‑formulated oral stimulants that optimize energy, focus, and cognitive performance. Through rigorous scientific research and advanced delivery technologies, we're pioneering next‑gen performance solutions designed to empower peak performance.

On behalf of the Board of Directors,
Chris Jackson
CEO
Doseology Sciences Inc.

For more information, please contact the Company at:
Email: hello@doseology.com
Website: www.doseology.com
Phone: 604.908.3095

 

Forward Looking Statements

This press release contains statements that constitute “forward‐looking information” within the meaning of applicable securities laws. Forward‐looking information is often identified by the words “may,” “would,” “could,” “should,” “will,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “expect” or similar expressions. Readers are cautioned that forward‐looking information is not based on historical facts but instead reflects the Company’s management’s expectations, estimates or projections concerning the business of the Company’s future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward‐looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance, or achievements. Among the key factors that could cause actual results to differ materially from those projected in the forward‐looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; decreases in the prevailing prices for products in the markets that the Company operates in; adverse changes in applicable laws or adverse changes in the application or enforcement of current laws; regulations and enforcement priorities of governmental authorities; compliance with government regulation and related costs; and other risks described in the Company’s


prospectus. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward‐looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated, or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward‐looking information except as otherwise required by applicable law. For more information, investors should review the Company’s filings which are available on SEDAR+.

No securities regulatory authority has either approved or disapproved of the contents of this press release.